199 lines
8.2 KiB
Plaintext
199 lines
8.2 KiB
Plaintext
|
|
|
|
|
|
|
|
(word processor parameters LM=8, RM=75, TM=2, BM=2)
|
|
Taken from KeelyNet BBS (214) 324-3501
|
|
Sponsored by Vangard Sciences
|
|
PO BOX 1031
|
|
Mesquite, TX 75150
|
|
|
|
There are ABSOLUTELY NO RESTRICTIONS
|
|
on duplicating, publishing or distributing the
|
|
files on KeelyNet except where noted!
|
|
|
|
June 6, 1993
|
|
|
|
HYPERBAR.ASC
|
|
--------------------------------------------------------------------
|
|
This file shared with KeelyNet courtesy of Mike Hughes.
|
|
--------------------------------------------------------------------
|
|
Date : Thu, 3 Jun 93 15:51:40 -0700
|
|
Subject: FATIGUE RELATED TO HIV/AIDS
|
|
From : Jeffry Skidmore <wombat@u.washington.edu>
|
|
|
|
ABSTRACT
|
|
|
|
HIV-Related Fatigue and Hyperbaric Oxygen Therapy
|
|
Reillo, M, R.N., B.S.N.,
|
|
Myers, R., M.D.,
|
|
HBO Staff, MIEMSS,
|
|
Baltimore, Maryland, USA
|
|
|
|
Objectives: Hyperbaric Oxygen Therapy (HBO) is being evaluated to
|
|
determine the effectiveness in relieving HIV-related
|
|
fatigue and determine the clinical and immunological
|
|
effects on HIV-infected individuals.
|
|
|
|
Methods: Twenty-five patients have been enrolled over a two-
|
|
year period. Admission criteria include chief
|
|
complaint of fatigue, seropositivity as confirmed by
|
|
ELISA and Western Blot for HIV infection, 500 CD4
|
|
cells or less, and absence of active opportunistic
|
|
infections which might compromise pulmonary or
|
|
neurologic function.
|
|
|
|
Twenty patients received 2 ATA, for 90 minutes, three
|
|
times per week.
|
|
|
|
Five patients voluntarily received surface air at the
|
|
same parameters to control for a placebo effect, and
|
|
then received 100% oxygen; all patients were treated
|
|
simultaneously in the HBO chamber. Withdrawal of HBO
|
|
therapy for one month was completed for 21 patients,
|
|
secondary to chamber construction.
|
|
|
|
Laboratory, clinical assessment, and Karnofsky Performance Scores
|
|
were completed monthly on all patients.
|
|
|
|
Results: All patients indicated relief of debilitating fatigue
|
|
within two weeks. Karnofsky Scores improved 10% to
|
|
30% within one month. Weights for all patients
|
|
|
|
|
|
Page 1
|
|
|
|
|
|
|
|
|
|
|
|
remained stable or increased; CD4, Hemoglobin, and
|
|
Hematocrit counts remained stable and/or increased.
|
|
|
|
Tumor Necrosis Factor decreased in 13 patients. P-24
|
|
antigens remained nonreactive or decreased if
|
|
reactive. Withdrawal of therapy for one month
|
|
secondary to new chamber construction for all but four
|
|
patients correlated with return of baseline fatigue
|
|
levels.
|
|
|
|
Additionally, two patients developed PCP and were treated outpatient
|
|
with dapsone and HBO via monoplace chamber.
|
|
|
|
One patient developed herpes zoster and was treated with zovirax and
|
|
HBO via monoplace chamber. After resuming HBO therapy, all
|
|
remaining patients returned to their six month Karnofsky Score,
|
|
which indicated significant improvement in their fatigue levels.
|
|
|
|
Twenty-three of the twenty-five patients have shown no clinical
|
|
disease progression; 80% of patients enrolled in the study have 50
|
|
CD4 cells or less.
|
|
|
|
Further, HBO appeared to relieve pain associated with peripheral
|
|
neuropathy in two patients and was a beneficial adjunct to the
|
|
treatment of mild PCP; the investigators have established protocols
|
|
to further investigate these findings.
|
|
|
|
Conclusion: The study is ongoing. HBO appears to be effective in
|
|
relieving HIV-related fatigue and improving the
|
|
quality of life of individuals with HIV/AIDS.
|
|
|
|
Preliminary research indicates a probable correlation with an
|
|
increase in length of employment capability, delayed disability
|
|
requirement, and reduction in number and length of hospitalizations
|
|
by incorporating HBO as a component in the medical management of HIV
|
|
disease.
|
|
|
|
The investigators believe HBO may relieve fatigue by inhibiting the
|
|
activity of certain cytokines, enhancing red blood cell production,
|
|
and enhancing the ability of HIV-impaired monocytes to absorb and
|
|
utilize oxygen.
|
|
|
|
The Center for Advancement of Hyperbaric Medicine is a Washington
|
|
corporation and has filed for IRS non-profit status as a 501(c)(3)
|
|
organization. CAHM's goals are:
|
|
|
|
1. To promote the acceptance and broadest appropriate application
|
|
of hyperbaric oxygen therapy in the professional medical
|
|
community.
|
|
|
|
2. To research and promote the research of promising applications
|
|
of hyperbaric oxygen therapy in a manner that will insure its
|
|
highest professional recognition and acceptance.
|
|
|
|
3. To collect, organize and disseminate all available information
|
|
about hyperbaric oxygen therapy so as to insure its most
|
|
knowledgeable application and implementation.
|
|
|
|
|
|
|
|
Page 2
|
|
|
|
|
|
|
|
|
|
|
|
4. To discover, research, develop and introduce new medical
|
|
applications for hyperbaric oxygen therapy.
|
|
|
|
5. To distinguish inappropriate, ineffective or fraudulent
|
|
application of hyperbaric oxygen therapy and to discourage
|
|
their practice.
|
|
|
|
Hyperbaric oxygen therapy consists of sitting in a closed chamber in
|
|
which the pressure is elevated to twice that at sea level (14.7 PSI
|
|
X 2 = 29.4 PSI 'pounds per square inch'), and then breathing pure
|
|
oxygen (while in the chamber).
|
|
|
|
The typical course of treatment is about 90 minutes two to three
|
|
times per week. This therapy is an established therapy for 13
|
|
recognized conditions and experimental in may more. It is practiced
|
|
in hospitals throughout the United States and the world.
|
|
|
|
The Center for Advancement of Hyperbaric Medicine can provide
|
|
treatment on your physicians prescription. This is *NOT A COMMERCIAL
|
|
VENTURE* the application to AIDS/HIV is experimental and
|
|
investigatory in nature.
|
|
|
|
CAHM can be reached at 1720 130th Ave. NE.,
|
|
Suite 103,
|
|
Bellevue, WA 98005,
|
|
Phone (206) 883-7819
|
|
FAX (206) 881-1795
|
|
|
|
or rapid pass along on INTERNET at wombat@u.washington.edu
|
|
--------------------------------------------------------------------
|
|
|
|
If you have comments or other information relating to such topics
|
|
as this paper covers, please upload to KeelyNet or send to the
|
|
Vangard Sciences address as listed on the first page.
|
|
Thank you for your consideration, interest and support.
|
|
|
|
Jerry W. Decker.........Ron Barker...........Chuck Henderson
|
|
Vangard Sciences/KeelyNet
|
|
|
|
--------------------------------------------------------------------
|
|
If we can be of service, you may contact
|
|
Jerry at (214) 324-8741 or Ron at (214) 242-9346
|
|
--------------------------------------------------------------------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page 3
|
|
|
|
|